Insights of Gouty Arthritis-Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Gouty Arthritis-Pipeline Review H1 2017” this report provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.
(EMAILWIRE.COM, June 16, 2017 ) Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 11, 2, 16, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/gouty-arthritis-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders) .
- The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001799306/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Allena Pharmaceuticals Inc
AstraZeneca Plc
C&C Research Laboratories
Cell Medica Ltd
CymaBay Therapeutics Inc
Genentech Inc
Immune Response BioPharma Inc
Jiangsu Hengrui Medicine Co Ltd
Monosol Rx LLC
Opsona Therapeutics Ltd
Polaris Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
Teijin Pharma Ltd
Wellstat Therapeutics Corp
XL-protein GmbH
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834313/discount
List of Tables
Number of Products under Development for Gouty Arthritis (Gout) , H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gouty Arthritis (Gout) - Pipeline by Allena Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H1 2017
Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H1 2017
Gouty Arthritis (Gout) - Pipeline by Cell Medica Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Genentech Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Monosol Rx LLC, H1 2017
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H1 2017
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corp, H1 2017
Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H1 2017
Gouty Arthritis (Gout) - Dormant Projects, H1 2017
Gouty Arthritis (Gout) - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Gouty Arthritis (Gout) - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834313/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 11, 2, 16, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/gouty-arthritis-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders) .
- The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001799306/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Allena Pharmaceuticals Inc
AstraZeneca Plc
C&C Research Laboratories
Cell Medica Ltd
CymaBay Therapeutics Inc
Genentech Inc
Immune Response BioPharma Inc
Jiangsu Hengrui Medicine Co Ltd
Monosol Rx LLC
Opsona Therapeutics Ltd
Polaris Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
Swedish Orphan Biovitrum AB
Teijin Pharma Ltd
Wellstat Therapeutics Corp
XL-protein GmbH
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834313/discount
List of Tables
Number of Products under Development for Gouty Arthritis (Gout) , H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gouty Arthritis (Gout) - Pipeline by Allena Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H1 2017
Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H1 2017
Gouty Arthritis (Gout) - Pipeline by Cell Medica Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Genentech Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Monosol Rx LLC, H1 2017
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H1 2017
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Ltd, H1 2017
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corp, H1 2017
Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H1 2017
Gouty Arthritis (Gout) - Dormant Projects, H1 2017
Gouty Arthritis (Gout) - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Gouty Arthritis (Gout) - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834313/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results